Most patients are at high risk of thrombosis during cancer treatment. However, the major
discrepancy in the therapeutic mechanisms and microenvironment between tumors and …

Venous thromboembolism (VTE) is a common cause of morbidity and mortality in
hospitalized patients. Globally, it is also the third leading vascular disease, after myocardial …

While nanomedicine research shows a great progress in the treatment of cancer, it still faces
challenges of tumor recurrence and metastasis. Numerous studies have demonstrated …

Introduction: Cancer-associated thrombosis (CAT) refers to the most common
thromboembolic complication of cancer which is venous thromboembolism (VTE). CAT …

Uvod: Limfomi predstavljaju vrlo heterogenu grupu neoplazmi, čija se biološka raznolikost
ogleda u različitim mehanizmima napredovanja bolesti i razvoja komplikacija. Jedna od …

Lymphomas represent a heterogeneous group of malignant hematological diseases with
high risk for development of venous thromboembolic complications (VTE). Consequently …

Venous thromboembolism (VTE) is a common cause of morbidity and mortality in
hospitalized patients. Globally, it is also the third leading vascular disease, after myocardial …

Sažetak Limfomi čine heterogenu grupu malignih hematoloških oboljenja koje karakteriše
visok rizik za razvoj venskih tromboembolijskih komplikacija (VTE), sa posledičnim …

Venous thromboembolism (VTE) is a major cause of morbidity and mortality in cancer
patients. Cancer patients have a four to sevenfold increased risk of VTE compared with non …